drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01233 | DB01235 | 1,311 | 1,191 | [
"DDInter1197",
"DDInter1054"
] | Metoclopramide | Levodopa | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
1311,
24,
1191
]
],
[
[
1311,
62,
817
],
[
817,
40,
1191
]
],
[
[
1311,
6,
12523
],
[
12523,
45,
1191
]
],
[
[
1311,
21,
28769
],
[
28... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Metoclopramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dopamine"
],
[
... | Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Dopamine and Dopamine (Compound) resembles Levodopa (Compound)
Metoclopramide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Levodopa (Compound)
Metoclopramide (Compound) causes Feeling abnormal (Side Effect) and ... |
DB00348 | DB01254 | 254 | 1,213 | [
"DDInter1300",
"DDInter484"
] | Nitisinone | Dasatinib | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
254,
24,
1213
]
],
[
[
254,
21,
28649
],
[
28649,
60,
1213
]
],
[
[
254,
24,
1247
],
[
1247,
23,
1213
]
],
[
[
254,
24,
563
],
[
563,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal haemorrhage"
],
[
"Gastrointestinal haemorrha... | Nitisinone (Compound) causes Gastrointestinal haemorrhage (Side Effect) and Gastrointestinal haemorrhage (Side Effect) is caused by Dasatinib (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can... |
DB00559 | DB00586 | 152 | 1,512 | [
"DDInter223",
"DDInter537"
] | Bosentan | Diclofenac | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
152,
24,
1512
]
],
[
[
152,
6,
8374
],
[
8374,
45,
1512
]
],
[
[
152,
21,
29231
],
[
29231,
60,
1512
]
],
[
[
152,
63,
752
],
[
752,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diclofenac (Compound)
Bosentan (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Diclofenac (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine ... |
DB00731 | DB06595 | 1,144 | 1,491 | [
"DDInter1269",
"DDInter1214"
] | Nateglinide | Midostaurin | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1144,
24,
1491
]
],
[
[
1144,
24,
112
],
[
112,
23,
1491
]
],
[
[
1144,
24,
761
],
[
761,
24,
1491
]
],
[
[
1144,
63,
888
],
[
888,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin an... |
DB06674 | DB08860 | 908 | 788 | [
"DDInter837",
"DDInter1479"
] | Golimumab | Pitavastatin | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Moderate | 1 | [
[
[
908,
24,
788
]
],
[
[
908,
63,
671
],
[
671,
1,
788
]
],
[
[
908,
63,
700
],
[
700,
40,
788
]
],
[
[
908,
63,
126
],
[
126,
23,
... | [
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastatin (Co... |
DB00332 | DB01619 | 1,089 | 830 | [
"DDInter970",
"DDInter1441"
] | Ipratropium | Phenindamine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1089,
24,
830
]
],
[
[
1089,
24,
537
],
[
537,
40,
830
]
],
[
[
1089,
63,
357
],
[
357,
24,
830
]
],
[
[
1089,
24,
13
],
[
13,
2... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine may cause a moderate interaction that... |
DB06643 | DB08889 | 1,136 | 350 | [
"DDInter500",
"DDInter299"
] | Denosumab | Carfilzomib | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
1136,
24,
350
]
],
[
[
1136,
63,
482
],
[
482,
24,
350
]
],
[
[
1136,
24,
310
],
[
310,
24,
350
]
],
[
[
1136,
24,
713
],
[
713,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazi... |
DB09079 | DB11095 | 1,496 | 235 | [
"DDInter1296",
"DDInter505"
] | Nintedanib | Desirudin | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Moderate | 1 | [
[
[
1496,
24,
235
]
],
[
[
1496,
63,
578
],
[
578,
24,
235
]
],
[
[
1496,
63,
1409
],
[
1409,
25,
235
]
],
[
[
1496,
24,
1421
],
[
1421,
... | [
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
... | Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban ... |
DB00662 | DB06282 | 717 | 516 | [
"DDInter1873",
"DDInter1053"
] | Trimethobenzamide | Levocetirizine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
717,
24,
516
]
],
[
[
717,
63,
701
],
[
701,
24,
516
]
],
[
[
717,
24,
1178
],
[
1178,
24,
516
]
],
[
[
717,
24,
1293
],
[
1293,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastin... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Tri... |
DB00295 | DB11901 | 475 | 913 | [
"DDInter1244",
"DDInter107"
] | Morphine | Apalutamide | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
475,
24,
913
]
],
[
[
475,
24,
1322
],
[
1322,
24,
913
]
],
[
[
475,
25,
1178
],
[
1178,
24,
913
]
],
[
[
475,
63,
1028
],
[
1028,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Morphine may lead to a major life threatening interaction when taken with Trifluoperazine and Trifluoperazine may... |
DB00539 | DB08820 | 11 | 1,478 | [
"DDInter1837",
"DDInter997"
] | Toremifene | Ivacaftor | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
11,
24,
1478
]
],
[
[
11,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
11,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
11,
24,
307
],
[
307,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Toremifene (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil... |
DB00357 | DB09049 | 1,051 | 1,135 | [
"DDInter71",
"DDInter1261"
] | Aminoglutethimide | Naloxegol | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Moderate | 1 | [
[
[
1051,
24,
1135
]
],
[
[
1051,
24,
807
],
[
807,
23,
1135
]
],
[
[
1051,
24,
971
],
[
971,
62,
1135
]
],
[
[
1051,
24,
1598
],
[
1598,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal and Ulipristal may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Gilteritin... |
DB00006 | DB01242 | 942 | 1,237 | [
"DDInter217",
"DDInter410"
] | Bivalirudin | Clomipramine | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
942,
24,
1237
]
],
[
[
942,
64,
1578
],
[
1578,
24,
1237
]
],
[
[
942,
24,
1274
],
[
1274,
24,
1237
]
],
[
[
942,
25,
498
],
[
498,
... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirud... | Bivalirudin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may ... |
DB00526 | DB12240 | 1,555 | 110 | [
"DDInter1355",
"DDInter1485"
] | Oxaliplatin | Polatuzumab vedotin | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
1555,
24,
110
]
],
[
[
1555,
24,
129
],
[
129,
23,
110
]
],
[
[
1555,
24,
467
],
[
467,
24,
110
]
],
[
[
1555,
63,
268
],
[
268,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Simvasta... |
DB00757 | DB13074 | 1,166 | 877 | [
"DDInter581",
"DDInter1110"
] | Dolasetron | Macimorelin | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1166,
25,
877
]
],
[
[
1166,
23,
112
],
[
112,
23,
877
]
],
[
[
1166,
40,
85
],
[
85,
24,
877
]
],
[
[
1166,
24,
673
],
[
673,
2... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Dolasetron (Compound) resembles Atropine (Compound) and Atropine may cause a moderate interaction that could ... |
DB00518 | DB00794 | 510 | 759 | [
"DDInter35",
"DDInter1521"
] | Albendazole | Primidone | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
510,
24,
759
]
],
[
[
510,
24,
697
],
[
697,
40,
759
]
],
[
[
510,
63,
362
],
[
362,
1,
759
]
],
[
[
510,
6,
7950
],
[
7950,
45,... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
... | Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compou... |
DB00471 | DB11652 | 201 | 1,155 | [
"DDInter1242",
"DDInter1891"
] | Montelukast | Tucatinib | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
201,
24,
1155
]
],
[
[
201,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
201,
24,
522
],
[
522,
24,
1155
]
],
[
[
201,
24,
1320
],
[
1320,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirl... |
DB00254 | DB00881 | 964 | 954 | [
"DDInter598",
"DDInter1554"
] | Doxycycline | Quinapril | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Moderate | 1 | [
[
[
964,
24,
954
]
],
[
[
964,
24,
1117
],
[
1117,
62,
954
]
],
[
[
964,
24,
1229
],
[
1229,
63,
954
]
],
[
[
964,
24,
663
],
[
663,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
],... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate and Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Quinapril
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Tetraf... |
DB00526 | DB01044 | 1,555 | 246 | [
"DDInter1355",
"DDInter809"
] | Oxaliplatin | Gatifloxacin | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Major | 2 | [
[
[
1555,
25,
246
]
],
[
[
1555,
24,
739
],
[
739,
1,
246
]
],
[
[
1555,
64,
1176
],
[
1176,
1,
246
]
],
[
[
1555,
25,
945
],
[
945,
... | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lome... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Oxaliplatin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)
O... |
DB09128 | DB11730 | 1,241 | 351 | [
"DDInter231",
"DDInter1588"
] | Brexpiprazole | Ribociclib | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1241,
25,
351
]
],
[
[
1241,
63,
222
],
[
222,
23,
351
]
],
[
[
1241,
25,
283
],
[
283,
62,
351
]
],
[
[
1241,
63,
1532
],
[
1532,
... | [
[
[
"Brexpiprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sib... | Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Brexpiprazole may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may ... |
DB00092 | DB06372 | 58 | 259 | [
"DDInter40",
"DDInter1594"
] | Alefacept | Rilonacept | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
58,
24,
259
]
],
[
[
58,
23,
1114
],
[
1114,
62,
259
]
],
[
[
58,
23,
1461
],
[
1461,
23,
259
]
],
[
[
58,
24,
0
],
[
0,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
... | Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E m... |
DB00056 | DB11793 | 816 | 738 | [
"DDInter814",
"DDInter1297"
] | Gemtuzumab ozogamicin | Niraparib | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
816,
24,
738
]
],
[
[
816,
24,
663
],
[
663,
24,
738
]
],
[
[
816,
63,
1253
],
[
1253,
24,
738
]
],
[
[
816,
25,
770
],
[
770,
2... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methot... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00446 | DB11978 | 597 | 124 | [
"DDInter351",
"DDInter822"
] | Chloramphenicol | Glasdegib | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
597,
24,
124
]
],
[
[
597,
25,
1135
],
[
1135,
23,
124
]
],
[
[
597,
24,
112
],
[
112,
23,
124
]
],
[
[
597,
23,
466
],
[
466,
6... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Na... | Chloramphenicol may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole... |
DB08870 | DB12825 | 850 | 1,375 | [
"DDInter228",
"DDInter1032"
] | Brentuximab vedotin | Lefamulin | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
850,
24,
1375
]
],
[
[
850,
63,
112
],
[
112,
23,
1375
]
],
[
[
850,
24,
159
],
[
159,
63,
1375
]
],
[
[
850,
63,
309
],
[
309,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidaz... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00342 | DB00834 | 1,181 | 932 | [
"DDInter1770",
"DDInter1215"
] | Terfenadine | Mifepristone | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Major | 2 | [
[
[
1181,
25,
932
]
],
[
[
1181,
63,
1101
],
[
1101,
23,
932
]
],
[
[
1181,
23,
112
],
[
112,
62,
932
]
],
[
[
1181,
24,
480
],
[
480,
... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mifepristone"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexaro... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mifepristone
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Met... |
DB01136 | DB12141 | 772 | 971 | [
"DDInter305",
"DDInter817"
] | Carvedilol | Gilteritinib | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
772,
24,
971
]
],
[
[
772,
24,
820
],
[
820,
24,
971
]
],
[
[
772,
24,
283
],
[
283,
63,
971
]
],
[
[
772,
63,
1010
],
[
1010,
2... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fe... |
DB00010 | DB00284 | 1,649 | 1,647 | [
"DDInter1661",
"DDInter11"
] | Sermorelin | Acarbose | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Moderate | 1 | [
[
[
1649,
24,
1647
]
],
[
[
1649,
24,
1645
],
[
1645,
62,
1647
]
],
[
[
1649,
24,
1021
],
[
1021,
63,
1647
]
],
[
[
1649,
24,
1645
],
[
16... | [
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
... | Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a minor interaction that can limit clinical effects when taken with Acarbose
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide... |
DB00637 | DB01149 | 1,557 | 851 | [
"DDInter128",
"DDInter1274"
] | Astemizole | Nefazodone | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Major | 2 | [
[
[
1557,
25,
851
]
],
[
[
1557,
63,
252
],
[
252,
40,
851
]
],
[
[
1557,
24,
1178
],
[
1178,
1,
851
]
],
[
[
1557,
24,
673
],
[
673,
... | [
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxyzi... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Nefazodone (Compound)
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Nefazodone... |
DB01362 | DB06077 | 497 | 879 | [
"DDInter960",
"DDInter1102"
] | Iohexol | Lumateperone | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Major | 2 | [
[
[
497,
25,
879
]
],
[
[
497,
64,
1645
],
[
1645,
24,
879
]
],
[
[
497,
25,
407
],
[
407,
63,
879
]
],
[
[
497,
25,
913
],
[
913,
6... | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cau... | Iohexol may lead to a major life threatening interaction when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Iohexol may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that cou... |
DB00350 | DB01170 | 1,214 | 1,150 | [
"DDInter1226",
"DDInter846"
] | Minoxidil | Guanethidine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Major | 2 | [
[
[
1214,
25,
1150
]
],
[
[
1214,
5,
11590
],
[
11590,
44,
1150
]
],
[
[
1214,
24,
1344
],
[
1344,
63,
1150
]
],
[
[
1214,
63,
475
],
[
47... | [
[
[
"Minoxidil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guanethidine"
]
],
[
[
"Minoxidil",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compo... | Minoxidil (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Guanethidine (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Gu... |
DB00604 | DB04948 | 1,425 | 1,084 | [
"DDInter385",
"DDInter1083"
] | Cisapride | Lofexidine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Major | 2 | [
[
[
1425,
25,
1084
]
],
[
[
1425,
23,
112
],
[
112,
23,
1084
]
],
[
[
1425,
25,
774
],
[
774,
63,
1084
]
],
[
[
1425,
24,
688
],
[
688,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lofexidine"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Cisapride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Cisapride may lead to a major life threatening interaction when taken with Degarelix and Degarelix may cause a ... |
DB01042 | DB14444 | 1,307 | 151 | [
"DDInter1144",
"DDInter924"
] | Melphalan | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
1307,
24,
151
]
],
[
[
1307,
63,
66
],
[
66,
24,
151
]
],
[
[
1307,
25,
375
],
[
375,
24,
151
]
],
[
[
1307,
24,
1531
],
[
1531,
... | [
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exa... | Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Melphalan may lead to a major life thr... |
DB00197 | DB09068 | 1,324 | 1,427 | [
"DDInter1881",
"DDInter1948"
] | Troglitazone | Vortioxetine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
1324,
24,
1427
]
],
[
[
1324,
24,
1320
],
[
1320,
63,
1427
]
],
[
[
1324,
24,
1220
],
[
1220,
24,
1427
]
],
[
[
1324,
23,
1101
],
[
11... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and D... |
DB00073 | DB10276 | 1,394 | 1,624 | [
"DDInter1608",
"DDInter1623"
] | Rituximab | Rotavirus vaccine | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1394,
25,
1624
]
],
[
[
1394,
25,
1583
],
[
1583,
64,
1624
]
],
[
[
1394,
25,
375
],
[
375,
25,
1624
]
],
[
[
1394,
24,
58
],
[
58,
... | [
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u... | Rituximab may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may lead to a major life threatening interaction when taken with Rotavirus vaccine
Rituximab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major l... |
DB00222 | DB01261 | 245 | 170 | [
"DDInter825",
"DDInter1679"
] | Glimepiride | Sitagliptin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
245,
24,
170
]
],
[
[
245,
5,
11640
],
[
11640,
44,
170
]
],
[
[
245,
21,
28921
],
[
28921,
60,
170
]
],
[
[
245,
23,
1103
],
[
1103,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Glimepiride",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
... | Glimepiride (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Sitagliptin (Compound)
Glimepiride (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin (Compound)
Glimepiride may cause a minor interaction that can limit clin... |
DB00564 | DB06372 | 1,236 | 259 | [
"DDInter293",
"DDInter1594"
] | Carbamazepine | Rilonacept | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
1236,
24,
259
]
],
[
[
1236,
24,
1619
],
[
1619,
63,
259
]
],
[
[
1236,
25,
1456
],
[
1456,
63,
259
]
],
[
[
1236,
24,
1573
],
[
1573,... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Carbamazepine may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may ca... |
DB00495 | DB06317 | 139 | 1,626 | [
"DDInter1961",
"DDInter630"
] | Zidovudine | Elotuzumab | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
139,
24,
1626
]
],
[
[
139,
24,
973
],
[
973,
24,
1626
]
],
[
[
139,
63,
597
],
[
597,
24,
1626
]
],
[
[
139,
24,
310
],
[
310,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and C... |
DB00414 | DB01261 | 590 | 170 | [
"DDInter16",
"DDInter1679"
] | Acetohexamide | Sitagliptin | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
590,
24,
170
]
],
[
[
590,
62,
1103
],
[
1103,
23,
170
]
],
[
[
590,
24,
52
],
[
52,
62,
170
]
],
[
[
590,
24,
623
],
[
623,
24,... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
... | Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Du... |
DB01182 | DB06616 | 371 | 594 | [
"DDInter1534",
"DDInter224"
] | Propafenone | Bosutinib | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
371,
24,
594
]
],
[
[
371,
6,
8374
],
[
8374,
45,
594
]
],
[
[
371,
21,
29231
],
[
29231,
60,
594
]
],
[
[
371,
62,
112
],
[
112,
... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Propafenone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Propafenone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Propafenone (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Propafenone may cause a minor interaction that can limit clinical effects when taken with Metron... |
DB01276 | DB04946 | 123 | 924 | [
"DDInter706",
"DDInter907"
] | Exenatide | Iloperidone | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
123,
24,
924
]
],
[
[
123,
63,
1664
],
[
1664,
1,
924
]
],
[
[
123,
63,
519
],
[
519,
40,
924
]
],
[
[
123,
63,
245
],
[
245,
24... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (Comp... |
DB01075 | DB11859 | 1,376 | 418 | [
"DDInter569",
"DDInter230"
] | Diphenhydramine | Brexanolone | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
1376,
24,
418
]
],
[
[
1376,
35,
820
],
[
820,
24,
418
]
],
[
[
1376,
74,
100
],
[
100,
24,
418
]
],
[
[
1376,
63,
104
],
[
104,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases w... | Diphenhydramine (Compound) resembles Alimemazine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Diphenhydramine (Compound) resembles Bro... |
DB00358 | DB01174 | 1,010 | 697 | [
"DDInter1140",
"DDInter1442"
] | Mefloquine | Phenobarbital | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
1010,
24,
697
]
],
[
[
1010,
24,
759
],
[
759,
1,
697
]
],
[
[
1010,
63,
362
],
[
362,
1,
697
]
],
[
[
1010,
24,
536
],
[
536,
4... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound... |
DB00903 | DB01285 | 1,680 | 708 | [
"DDInter686",
"DDInter445"
] | Etacrynic acid | Corticotropin | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1680,
24,
708
]
],
[
[
1680,
24,
455
],
[
455,
23,
708
]
],
[
[
1680,
24,
659
],
[
659,
62,
708
]
],
[
[
1680,
63,
1674
],
[
1674,
... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol a... |
DB00060 | DB00480 | 912 | 1,668 | [
"DDInter947",
"DDInter1035"
] | Interferon beta-1a | Lenalidomide | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Moderate | 1 | [
[
[
912,
24,
1668
]
],
[
[
912,
24,
126
],
[
126,
62,
1668
]
],
[
[
912,
24,
384
],
[
384,
63,
1668
]
],
[
[
912,
24,
482
],
[
482,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Lenalidomide
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisi... |
DB06016 | DB08882 | 1,508 | 1,281 | [
"DDInter300",
"DDInter1070"
] | Cariprazine | Linagliptin | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1508,
24,
1281
]
],
[
[
1508,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1508,
24,
1320
],
[
1320,
63,
1281
]
],
[
[
1508,
24,
868
],
[
868,... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could ... |
DB00285 | DB01268 | 1,100 | 1,151 | [
"DDInter1927",
"DDInter1731"
] | Venlafaxine | Sunitinib | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1100,
24,
1151
]
],
[
[
1100,
24,
1311
],
[
1311,
1,
1151
]
],
[
[
1100,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
1100,
21,
29662
],
[
296... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Venlafaxine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Venlafaxine (Compound) causes Candida infection (Side Effect... |
DB00502 | DB00986 | 1,300 | 1,192 | [
"DDInter853",
"DDInter834"
] | Haloperidol | Glycopyrronium | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Moderate | 1 | [
[
[
1300,
24,
1192
]
],
[
[
1300,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
1300,
24,
262
],
[
262,
24,
1192
]
],
[
[
1300,
21,
29231
],
[
292... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and... |
DB00643 | DB09293 | 1,370 | 116 | [
"DDInter1128",
"DDInter954"
] | Mebendazole | Iodide I-131 | A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem] | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
1370,
24,
116
]
],
[
[
1370,
24,
112
],
[
112,
24,
116
]
],
[
[
1370,
40,
510
],
[
510,
24,
116
]
],
[
[
1370,
24,
112
],
[
112,
... | [
[
[
"Mebendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Mebendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Mebendazole may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Mebendazole (Compound) resembles Albendazole (Compound) and Albendazole may cause a moderate interactio... |
DB00307 | DB06717 | 1,101 | 875 | [
"DDInter202",
"DDInter778"
] | Bexarotene | Fosaprepitant | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Minor | 0 | [
[
[
1101,
23,
875
]
],
[
[
1101,
23,
723
],
[
723,
1,
875
]
],
[
[
1101,
21,
29180
],
[
29180,
60,
875
]
],
[
[
1101,
24,
466
],
[
466,
... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
],
[
... | Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Bexarotene (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosaprepitant (Compound)
Bexarotene may cau... |
DB04837 | DB06077 | 649 | 879 | [
"DDInter407",
"DDInter1102"
] | Clofedanol | Lumateperone | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
649,
24,
879
]
],
[
[
649,
24,
407
],
[
407,
63,
879
]
],
[
[
649,
1,
1511
],
[
1511,
24,
879
]
],
[
[
649,
63,
717
],
[
717,
24... | [
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Clofedanol (Compound) resembles Mepenzolate (Compound) and Mepenzolate may cause a moderate interaction that could exace... |
DB01166 | DB04948 | 477 | 1,084 | [
"DDInter379",
"DDInter1083"
] | Cilostazol | Lofexidine | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
477,
24,
1084
]
],
[
[
477,
62,
112
],
[
112,
23,
1084
]
],
[
[
477,
63,
618
],
[
618,
24,
1084
]
],
[
[
477,
24,
774
],
[
774,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarel... |
DB01036 | DB09076 | 211 | 1,116 | [
"DDInter1832",
"DDInter1899"
] | Tolterodine | Umeclidinium | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
211,
24,
1116
]
],
[
[
211,
24,
849
],
[
849,
24,
1116
]
],
[
[
211,
1,
358
],
[
358,
24,
1116
]
],
[
[
211,
63,
1442
],
[
1442,
... | [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Tolterodine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction th... |
DB00741 | DB00978 | 167 | 739 | [
"DDInter885",
"DDInter1084"
] | Hydrocortisone | Lomefloxacin | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Major | 2 | [
[
[
167,
25,
739
]
],
[
[
167,
25,
945
],
[
945,
40,
739
]
],
[
[
167,
64,
1176
],
[
1176,
1,
739
]
],
[
[
167,
64,
1467
],
[
1467,
... | [
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin"... | Hydrocortisone may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Hydrocortisone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (Compound)
Hydrocorti... |
DB00675 | DB01174 | 888 | 697 | [
"DDInter1744",
"DDInter1442"
] | Tamoxifen | Phenobarbital | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
888,
24,
697
]
],
[
[
888,
24,
759
],
[
759,
1,
697
]
],
[
[
888,
63,
362
],
[
362,
1,
697
]
],
[
[
888,
63,
536
],
[
536,
40,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound)
... |
DB06692 | DB11330 | 930 | 979 | [
"DDInter113",
"DDInter709"
] | Aprotinin | Factor IX Complex (Human) | Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal o... | Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (St... | Major | 2 | [
[
[
930,
25,
979
]
],
[
[
930,
63,
20
],
[
20,
24,
335
],
[
335,
25,
979
]
],
[
[
930,
25,
1380
],
[
1380,
64,
335
],
[
335,
25,
9... | [
[
[
"Aprotinin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Factor IX Complex (Human)"
]
],
[
[
"Aprotinin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
... | Aprotinin may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Tranexamic acid and Tranexamic acid may lead to a major life threatening interaction when taken with Factor IX Complex (... |
DB01250 | DB14761 | 712 | 242 | [
"DDInter1334",
"DDInter1578"
] | Olsalazine | Remdesivir | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
712,
24,
242
]
],
[
[
712,
63,
1512
],
[
1512,
24,
242
]
],
[
[
712,
64,
629
],
[
629,
24,
242
]
],
[
[
712,
1,
50
],
[
50,
24,
... | [
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
... | Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Olsalazine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a ... |
DB01203 | DB08884 | 699 | 796 | [
"DDInter1255",
"DDInter800"
] | Nadolol | Gadoxetic acid | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing ionic linear contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection. Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up ... | Moderate | 1 | [
[
[
699,
24,
796
]
],
[
[
699,
63,
457
],
[
457,
1,
796
]
],
[
[
699,
24,
1106
],
[
1106,
1,
796
]
],
[
[
699,
21,
28841
],
[
28841,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoxetic acid"
]
],
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
],
[
... | Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadoxetic acid (Compound)
Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium (Compound) resemble... |
DB00095 | DB06603 | 66 | 39 | [
"DDInter623",
"DDInter1387"
] | Efalizumab | Panobinostat | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
66,
24,
39
]
],
[
[
66,
24,
221
],
[
221,
63,
39
]
],
[
[
66,
63,
58
],
[
58,
24,
39
]
],
[
[
66,
24,
1683
],
[
1683,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Efalizumab may cause a mod... |
DB05351 | DB08931 | 101 | 947 | [
"DDInter519",
"DDInter1600"
] | Dexlansoprazole | Riociguat | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation... | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Moderate | 1 | [
[
[
101,
24,
947
]
],
[
[
101,
63,
609
],
[
609,
24,
947
]
],
[
[
101,
64,
1195
],
[
1195,
24,
947
]
],
[
[
101,
63,
609
],
[
609,
2... | [
[
[
"Dexlansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Dexlansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
... | Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Dexlansoprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlot... |
DB00853 | DB08827 | 1,686 | 990 | [
"DDInter1762",
"DDInter1085"
] | Temozolomide | Lomitapide | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1686,
25,
990
]
],
[
[
1686,
6,
8374
],
[
8374,
45,
990
]
],
[
[
1686,
21,
28701
],
[
28701,
60,
990
]
],
[
[
1686,
24,
1362
],
[
1362... | [
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Temozolomide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lom... | Temozolomide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Temozolomide (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Lomitapide (Compound)
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib an... |
DB08865 | DB12130 | 1,593 | 1,017 | [
"DDInter448",
"DDInter1094"
] | Crizotinib | Lorlatinib | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1593,
24,
1017
]
],
[
[
1593,
25,
1612
],
[
1612,
23,
1017
]
],
[
[
1593,
23,
271
],
[
271,
23,
1017
]
],
[
[
1593,
63,
1101
],
[
1101... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Fostemsav... | Crizotinib may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a ... |
DB00675 | DB06636 | 888 | 1,623 | [
"DDInter1744",
"DDInter980"
] | Tamoxifen | Isavuconazonium | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
888,
24,
1623
]
],
[
[
888,
63,
1419
],
[
1419,
24,
1623
]
],
[
[
888,
25,
1487
],
[
1487,
24,
1623
]
],
[
[
888,
24,
1213
],
[
1213,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Tamoxifen may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroq... |
DB00524 | DB00902 | 811 | 104 | [
"DDInter1199",
"DDInter1168"
] | Metolazone | Methdilazine | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
811,
24,
104
]
],
[
[
811,
24,
820
],
[
820,
1,
104
]
],
[
[
811,
24,
401
],
[
401,
63,
104
]
],
[
[
811,
24,
286
],
[
286,
62,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction th... |
DB00305 | DB09498 | 377 | 810 | [
"DDInter1232",
"DDInter1715"
] | Mitomycin | Strontium chloride Sr-89 | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
377,
24,
810
]
],
[
[
377,
63,
552
],
[
552,
24,
810
]
],
[
[
377,
24,
1555
],
[
1555,
24,
810
]
],
[
[
377,
25,
970
],
[
970,
2... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
... | Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplat... |
DB06414 | DB08865 | 655 | 1,593 | [
"DDInter703",
"DDInter448"
] | Etravirine | Crizotinib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
655,
24,
1593
]
],
[
[
655,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
655,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
655,
25,
283
],
[
283,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Etravirine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Etravirine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Etravirine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Etravirine may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a ... |
DB00047 | DB09100 | 176 | 320 | [
"DDInter932",
"DDInter1799"
] | Insulin glargine | Thyroid, porcine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
176,
24,
320
]
],
[
[
176,
24,
417
],
[
417,
23,
320
]
],
[
[
176,
24,
127
],
[
127,
24,
320
]
],
[
[
176,
24,
433
],
[
433,
63,... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfat... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Migli... |
DB00069 | DB00495 | 367 | 139 | [
"DDInter946",
"DDInter1961"
] | Interferon alfacon-1 | Zidovudine | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Major | 2 | [
[
[
367,
25,
139
]
],
[
[
367,
25,
1477
],
[
1477,
40,
139
]
],
[
[
367,
24,
231
],
[
231,
40,
139
]
],
[
[
367,
24,
309
],
[
309,
6... | [
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telbivudine"
],
[
"Telb... | Interferon alfacon-1 may lead to a major life threatening interaction when taken with Telbivudine and Telbivudine (Compound) resembles Zidovudine (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine (Compound) resembles Zidovudine (Compo... |
DB00827 | DB01124 | 646 | 1,411 | [
"DDInter383",
"DDInter1828"
] | Cinoxacin | Tolbutamide | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Major | 2 | [
[
[
646,
25,
1411
]
],
[
[
646,
25,
959
],
[
959,
40,
1411
]
],
[
[
646,
64,
245
],
[
245,
40,
1411
]
],
[
[
646,
6,
10612
],
[
10612,
... | [
[
[
"Cinoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolbutamide"
]
],
[
[
"Cinoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Com... | Cinoxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Cinoxacin may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Cinoxacin (Compound) binds SLC... |
DB01149 | DB09098 | 851 | 98 | [
"DDInter1274",
"DDInter1700"
] | Nefazodone | Somatrem | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
851,
24,
98
]
],
[
[
851,
63,
608
],
[
608,
23,
98
]
],
[
[
851,
24,
284
],
[
284,
24,
98
]
],
[
[
851,
25,
159
],
[
159,
63,
... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Finasteride and Finasteride... |
DB01166 | DB08875 | 477 | 1,618 | [
"DDInter379",
"DDInter262"
] | Cilostazol | Cabozantinib | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
477,
25,
1618
]
],
[
[
477,
62,
112
],
[
112,
23,
1618
]
],
[
[
477,
64,
723
],
[
723,
24,
1618
]
],
[
[
477,
25,
384
],
[
384,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Cilostazol may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may ca... |
DB00370 | DB00792 | 1,251 | 832 | [
"DDInter1230",
"DDInter1878"
] | Mirtazapine | Tripelennamine | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1251,
24,
832
]
],
[
[
1251,
24,
100
],
[
100,
63,
832
]
],
[
[
1251,
25,
1264
],
[
1264,
63,
832
]
],
[
[
1251,
24,
649
],
[
649,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Mirtazapine may lead to a major life threatening interaction when taken with Doxepin and Doxepin ... |
DB00612 | DB09080 | 1,121 | 144 | [
"DDInter216",
"DDInter1331"
] | Bisoprolol | Olodaterol | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1121,
24,
144
]
],
[
[
1121,
25,
1011
],
[
1011,
24,
144
]
],
[
[
1121,
24,
1445
],
[
1445,
24,
144
]
],
[
[
1121,
64,
1031
],
[
1031,... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Bisoprolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod... | Bisoprolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine ... |
DB00651 | DB09082 | 746 | 659 | [
"DDInter613",
"DDInter1934"
] | Dyphylline | Vilanterol | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
746,
24,
659
]
],
[
[
746,
64,
88
],
[
88,
24,
659
]
],
[
[
746,
24,
1674
],
[
1674,
24,
659
]
],
[
[
746,
25,
419
],
[
419,
24,... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoprolol"
],
[
"Metoprolol... | Dyphylline may lead to a major life threatening interaction when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may ... |
DB06209 | DB08816 | 256 | 578 | [
"DDInter1508",
"DDInter1802"
] | Prasugrel | Ticagrelor | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
256,
24,
578
]
],
[
[
256,
6,
17955
],
[
17955,
45,
578
]
],
[
[
256,
54,
19259
],
[
19259,
15,
578
]
],
[
[
256,
21,
28646
],
[
28646... | [
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Prasugrel",
"{u} (Compound) binds {v} (Gene)",
"P2RY12"
],
[
"P2RY12",
"{u} (Gene) is bound by {v} (Compound)",
... | Prasugrel (Compound) binds P2RY12 (Gene) and P2RY12 (Gene) is bound by Ticagrelor (Compound)
Prasugrel (Compound) is included by P2Y12 Receptor Antagonists (Pharmacologic Class) and P2Y12 Receptor Antagonists (Pharmacologic Class) includes Ticagrelor (Compound)
Prasugrel (Compound) causes Unspecified disorder of skin a... |
DB00620 | DB06186 | 175 | 1,439 | [
"DDInter1855",
"DDInter969"
] | Triamcinolone | Ipilimumab | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
175,
24,
1439
]
],
[
[
175,
1,
617
],
[
617,
24,
1439
]
],
[
[
175,
24,
1412
],
[
1412,
63,
1439
]
],
[
[
175,
40,
1486
],
[
1486,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a m... | Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate ... |
DB00615 | DB06697 | 690 | 436 | [
"DDInter1589",
"DDInter121"
] | Rifabutin | Artemether | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</... | Moderate | 1 | [
[
[
690,
24,
436
]
],
[
[
690,
6,
8374
],
[
8374,
45,
436
]
],
[
[
690,
25,
283
],
[
283,
63,
436
]
],
[
[
690,
24,
1220
],
[
1220,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Artemether"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Artemether (Compound)
Rifabutin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Rifabutin may cause a moderate inte... |
DB00242 | DB00426 | 1,064 | 3 | [
"DDInter392",
"DDInter711"
] | Cladribine | Famciclovir | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Famciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles). Famciclovir is a prodrug of penciclovir with higher oral bioavailability. | Moderate | 1 | [
[
[
1064,
24,
3
]
],
[
[
1064,
7,
18110
],
[
18110,
46,
3
]
],
[
[
1064,
18,
17366
],
[
17366,
57,
3
]
],
[
[
1064,
21,
29340
],
[
29340,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famciclovir"
]
],
[
[
"Cladribine",
"{u} (Compound) upregulates {v} (Gene)",
"ST6GALNAC2"
],
[
"ST6GALNAC2",
"{u} (Gene) is upregulate... | Cladribine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Famciclovir (Compound)
Cladribine (Compound) downregulates C2CD5 (Gene) and C2CD5 (Gene) is downregulated by Famciclovir (Compound)
Cladribine (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome... |
DB01001 | DB01263 | 688 | 859 | [
"DDInter1632",
"DDInter1494"
] | Salbutamol | Posaconazole | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
688,
24,
859
]
],
[
[
688,
6,
8374
],
[
8374,
45,
859
]
],
[
[
688,
21,
28762
],
[
28762,
60,
859
]
],
[
[
688,
62,
112
],
[
112,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Salbutamol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Salbutamol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and M... |
DB00959 | DB01132 | 1,486 | 1,130 | [
"DDInter1191",
"DDInter1472"
] | Methylprednisolone | Pioglitazone | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1486,
24,
1130
]
],
[
[
1486,
6,
8374
],
[
8374,
45,
1130
]
],
[
[
1486,
18,
5057
],
[
5057,
46,
1130
]
],
[
[
1486,
21,
28661
],
[
28... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound b... | Methylprednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pioglitazone (Compound)
Methylprednisolone (Compound) downregulates IL1B (Gene) and IL1B (Gene) is upregulated by Pioglitazone (Compound)
Methylprednisolone (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome... |
DB01064 | DB06292 | 1,148 | 549 | [
"DDInter987",
"DDInter474"
] | Isoprenaline | Dapagliflozin | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
1148,
24,
549
]
],
[
[
1148,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1148,
6,
9842
],
[
9842,
45,
549
]
],
[
[
1148,
21,
28762
],
[
28762... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Isoprenaline (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dapagliflozin (Compound)
Isoprenaline (Compound) causes Headache (Side Effe... |
DB00388 | DB09043 | 1,636 | 135 | [
"DDInter1453",
"DDInter36"
] | Phenylephrine | Albiglutide | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1636,
24,
135
]
],
[
[
1636,
24,
1252
],
[
1252,
23,
135
]
],
[
[
1636,
63,
1647
],
[
1647,
23,
135
]
],
[
[
1636,
24,
1052
],
[
1052,... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose ... |
DB01218 | DB01263 | 1,493 | 859 | [
"DDInter852",
"DDInter1494"
] | Halofantrine | Posaconazole | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Major | 2 | [
[
[
1493,
25,
859
]
],
[
[
1493,
6,
8374
],
[
8374,
45,
859
]
],
[
[
1493,
21,
28762
],
[
28762,
60,
859
]
],
[
[
1493,
62,
112
],
[
112,
... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
],
[
[
"Halofantrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"P... | Halofantrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Halofantrine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Metronidazole... |
DB00213 | DB00999 | 837 | 504 | [
"DDInter1388",
"DDInter883"
] | Pantoprazole | Hydrochlorothiazide | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Moderate | 1 | [
[
[
837,
24,
504
]
],
[
[
837,
24,
178
],
[
178,
1,
504
]
],
[
[
837,
24,
323
],
[
323,
40,
504
]
],
[
[
837,
21,
29561
],
[
29561,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compoun... |
DB00346 | DB12332 | 472 | 1,619 | [
"DDInter44",
"DDInter1626"
] | Alfuzosin | Rucaparib | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
472,
24,
1619
]
],
[
[
472,
23,
112
],
[
112,
23,
1619
]
],
[
[
472,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
472,
24,
159
],
[
159,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Alfuzosin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and ... |
DB00450 | DB12332 | 78 | 1,619 | [
"DDInter603",
"DDInter1626"
] | Droperidol | Rucaparib | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
78,
25,
1619
]
],
[
[
78,
24,
222
],
[
222,
23,
1619
]
],
[
[
78,
23,
112
],
[
112,
23,
1619
]
],
[
[
78,
25,
1662
],
[
1662,
24... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramin... | Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Droperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metron... |
DB00242 | DB00928 | 1,064 | 1,426 | [
"DDInter392",
"DDInter148"
] | Cladribine | Azacitidine | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Major | 2 | [
[
[
1064,
25,
1426
]
],
[
[
1064,
1,
1585
],
[
1585,
40,
1426
]
],
[
[
1064,
36,
1238
],
[
1238,
40,
1426
]
],
[
[
1064,
40,
11243
],
[
11... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azacitidine"
]
],
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound)",
"Adenosine"
],
[
"Adenosine",
"{u} (Compound) resembles {v} (Compound)... | Cladribine (Compound) resembles Adenosine (Compound) and Adenosine (Compound) resembles Azacitidine (Compound)
Cladribine (Compound) resembles Pentostatin (Compound) and Cladribine may lead to a major life threatening interaction when taken with Pentostatin and Pentostatin (Compound) resembles Azacitidine (Compound)
Cl... |
DB00361 | DB00888 | 134 | 1,001 | [
"DDInter1939",
"DDInter1133"
] | Vinorelbine | Mechlorethamine | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Moderate | 1 | [
[
[
134,
24,
1001
]
],
[
[
134,
24,
450
],
[
450,
1,
1001
]
],
[
[
134,
5,
11555
],
[
11555,
44,
1001
]
],
[
[
134,
21,
30038
],
[
30038,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Vinorelbine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Mechlorethamine (Compound)
Vinorelbi... |
DB00281 | DB00507 | 608 | 316 | [
"DDInter1066",
"DDInter1299"
] | Lidocaine | Nitazoxanide | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Nitazoxanide belongs to the class of drugs known as _thiazolides_. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses.... | Moderate | 1 | [
[
[
608,
24,
316
]
],
[
[
608,
21,
28787
],
[
28787,
60,
316
]
],
[
[
608,
24,
481
],
[
481,
63,
316
]
],
[
[
608,
63,
1174
],
[
1174,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitazoxanide"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is ca... | Lidocaine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nitazoxanide (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Nitazoxan... |
DB00701 | DB09104 | 1,091 | 286 | [
"DDInter90",
"DDInter1118"
] | Amprenavir | Magnesium hydroxide | Amprenavir is a protease inhibitor used to treat HIV infection. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1091,
24,
286
]
],
[
[
1091,
62,
752
],
[
752,
23,
286
]
],
[
[
1091,
25,
263
],
[
263,
23,
286
]
],
[
[
1091,
25,
1593
],
[
1593,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Amprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
... | Amprenavir may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Amprenavir may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause... |
DB00224 | DB01276 | 215 | 123 | [
"DDInter917",
"DDInter706"
] | Indinavir | Exenatide | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
215,
24,
123
]
],
[
[
215,
25,
1476
],
[
1476,
63,
123
]
],
[
[
215,
24,
1573
],
[
1573,
24,
123
]
],
[
[
215,
24,
1040
],
[
1040,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
... | Indinavir may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a m... |
DB01611 | DB09082 | 1,487 | 659 | [
"DDInter893",
"DDInter1934"
] | Hydroxychloroquine | Vilanterol | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1487,
24,
659
]
],
[
[
1487,
64,
1570
],
[
1570,
24,
659
]
],
[
[
1487,
24,
1296
],
[
1296,
63,
659
]
],
[
[
1487,
25,
927
],
[
927,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azithromycin"
],
[... | Hydroxychloroquine may lead to a major life threatening interaction when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec... |
DB00883 | DB06691 | 426 | 849 | [
"DDInter989",
"DDInter1155"
] | Isosorbide dinitrate | Mepyramine | A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
426,
24,
849
]
],
[
[
426,
24,
407
],
[
407,
63,
849
]
],
[
[
426,
24,
1376
],
[
1376,
24,
849
]
],
[
[
426,
40,
1107
],
[
1107,
... | [
[
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
... | Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydra... |
DB11560 | DB11703 | 1,678 | 405 | [
"DDInter1038",
"DDInter9"
] | Lesinurad | Acalabrutinib | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1678,
24,
405
]
],
[
[
1678,
24,
1297
],
[
1297,
63,
405
]
],
[
[
1678,
63,
86
],
[
86,
24,
405
]
],
[
[
1678,
63,
1409
],
[
1409,
... | [
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[... | Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and M... |
DB08912 | DB12301 | 1,040 | 907 | [
"DDInter462",
"DDInter585"
] | Dabrafenib | Doravirine | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Major | 2 | [
[
[
1040,
25,
907
]
],
[
[
1040,
63,
1478
],
[
1478,
23,
907
]
],
[
[
1040,
24,
159
],
[
159,
62,
907
]
],
[
[
1040,
24,
951
],
[
951,
... | [
[
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doravirine"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",... | Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotre... |
DB00607 | DB08820 | 1,249 | 1,478 | [
"DDInter1256",
"DDInter997"
] | Nafcillin | Ivacaftor | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
1249,
24,
1478
]
],
[
[
1249,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1249,
21,
29106
],
[
29106,
60,
1478
]
],
[
[
1249,
24,
1135
],
[
1... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Nafcillin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Nafcillin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Nafcillin (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Ivacaftor (Compound)
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may ... |
DB06448 | DB12141 | 171 | 971 | [
"DDInter1087",
"DDInter817"
] | Lonafarnib | Gilteritinib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
171,
25,
971
]
],
[
[
171,
25,
1135
],
[
1135,
23,
971
]
],
[
[
171,
24,
466
],
[
466,
62,
971
]
],
[
[
171,
63,
112
],
[
112,
2... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Lonafarnib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may caus... |
DB01156 | DB01191 | 593 | 1,039 | [
"DDInter252",
"DDInter518"
] | Bupropion | Dexfenfluramine | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Major | 2 | [
[
[
593,
25,
1039
]
],
[
[
593,
25,
1529
],
[
1529,
64,
1039
]
],
[
[
593,
6,
12523
],
[
12523,
45,
1039
]
],
[
[
593,
62,
211
],
[
211,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
... | Bupropion may lead to a major life threatening interaction when taken with Metamfetamine and Metamfetamine may lead to a major life threatening interaction when taken with Dexfenfluramine
Bupropion (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dexfenfluramine (Compound)
Bupropion may cause a minor intera... |
DB01058 | DB08899 | 978 | 129 | [
"DDInter1510",
"DDInter649"
] | Praziquantel | Enzalutamide | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
978,
25,
129
]
],
[
[
978,
6,
8374
],
[
8374,
45,
129
]
],
[
[
978,
21,
28703
],
[
28703,
60,
129
]
],
[
[
978,
24,
1320
],
[
1320,
... | [
[
[
"Praziquantel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Praziquantel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"E... | Praziquantel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Praziquantel (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Elagolix an... |
DB00295 | DB00924 | 475 | 1,405 | [
"DDInter1244",
"DDInter454"
] | Morphine | Cyclobenzaprine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Major | 2 | [
[
[
475,
25,
1405
]
],
[
[
475,
24,
649
],
[
649,
63,
1405
]
],
[
[
475,
24,
1302
],
[
1302,
1,
1405
]
],
[
[
475,
25,
358
],
[
358,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedano... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Pr... |
DB00622 | DB12010 | 1,081 | 214 | [
"DDInter1287",
"DDInter785"
] | Nicardipine | Fostamatinib | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1081,
24,
214
]
],
[
[
1081,
40,
1428
],
[
1428,
24,
214
]
],
[
[
1081,
24,
723
],
[
723,
24,
214
]
],
[
[
1081,
63,
600
],
[
600,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a mod... | Nicardipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that c... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.